Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias

Clinical Neuropharmacology

Volumn 20, Issue 2, 1997, Pages 95-115

  Stocchi, Fabrizio ^a   Nordera, Giampietro ^c   Marsden, C David ^b,d  

^a Mediterranean Institute of Neuroscience   (Italy)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^c Istituto Antonio Benedetti   (Italy)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Advanced PD; Dyskinesias; Levodopa; Psychotoxicity

Indexed keywords

AMITRIPTYLINE; ANTIHISTAMINIC AGENT; APOMORPHINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CISAPRIDE; CLONAZEPAM; DESMOPRESSIN; DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; FLUDROCORTISONE; FLUVOXAMINE; LEVODOPA; LISURIDE; LORAZEPAM; MIDODRINE; OXYBUTYNIN; PROPANTHELINE BROMIDE; SELEGILINE; YOHIMBINE;

DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DYSKINESIA; HUMAN; HUMAN CELL; HUMAN TISSUE; LONG TERM CARE; NEUROTOXICITY; PARKINSON DISEASE; PRIORITY JOURNAL; PROBLEM SOLVING; REVIEW; SLEEP DISORDER; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030951005     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199704000-00001     Document Type: Review

References (146)

1. Clarke CE. Does levodopa therapy delay death in Parkinson's disease? A review of the evidence. Mov Disord 1995;10:250-62.
2. Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1977;1:345-9.
3. Marsden CD. Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:672-81.
4. Luquin MR, Scipioni O, Vaamonde J, Gershanik O, Obeso JA. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov Disord 1992;7:117-24.
5. Marconi R, Lefebvre-Caparros D, Bonnet A-M, Vidailhet M, Dubois B, Agid Y. Levodopa-induced dyskinesias in Parkinson's disease: phenomenology and pathophysiology. Mov Disord 1994;9:2-12.
6. Melamed E, Bitton V, Zelig O. Episodic unresponsiveness to single doses of L-Dopa in parkinsonian fluctuators. Neurology 1986;36:100-3.
7. Quinn N, Critchley P, Marsden CD. Young onset Parkinson's disease. Mov Disord 1987;2:73-91.
8. Kostic V, Przedborski S, Flaster E, Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 1991;41:202-5.
9. Marsden CD, Parkes JD. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976;1:292-6.
10. Marsden CD, Parkes JD, Quinn N. Fluctuations of disability in Parkinson's disease - clinical aspects. In: Marsden CD, Fahn S, eds. Movement disorders. London: Butterworth Scientific, 1982:123-45.
11. Calne DB. Treatment of Parkinson's disease. N Engl J Med 1993;329:1021-7.
12. Lees AJ, Shaw KM, Kohout LJ, et al. Deprenyl in Parkinson's disease. Lancet 1977;2-791-5.
13. Golbe LI, Lieberman AN, Muenter MD, Ahlskog JE, Gopinathan G. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin Neuropharmacol 1988;11:45-55.
14. Factor SA, Weiner WJ. Early combination therapy with bromocriptine and levodopa in Parkinson's disease. Mov Disord 1993;8:257-62.
15. Poewe WH, Lees AJ, Stern GM. Treatment of motor fluctuations in Parkinson's disease with an oral sustained-release preparation of L-dopa: clinical and pharmacokinetic observations. Clin Neuropharmacol 1986;9:430-9.
16. Cedarbaum JM, Breck L, Kutt H, et al. Controlled-release levodopa/carbidopa. I. Sinemet CR-3 treatment of response fluctuation in Parkinson's disease. Neurology 1987;37:233-41.
17. Pezzoli G, Tesei S, Ferrante C, Cossutta E, Zecchinelli A, Scarlato G. Madopar HBS in fluctuating parkinsonian patients: two-year treatment. Mov Disord 1988;-3:37-45.
18. Jankovic J, Schwartz K, Van der Linden C. Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations. Mov Disord 1989;4:303-9.
19. Stocchi F, Bragoni M, Monge A, et al. Oral sustained-release preparation of L-Dopa in the management of fluctuations in Parkinson's disease: 6 months follow-up. N Trends Clin Neuropharmacol 1989;12:543-55.
20. Nutt JG. On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics. Ann Neurol 1987;22:535-40.
21. Wooten GF. Progress in understanding the pathophysiology of treatment-related fluctuations in Parkinson's disease. Ann Neurol 1988;24:363-5.
22. Mouradian MM, Heuser IJE, Baronti F, Fabbrini G, Juncos JL, Chase TN. Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol 1989;25:523-6.
23. Fabbrini G, Juncos J, Mouradian MM, Serrati C, Chase TN. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol 1987;21:370-6.
24. Fabbrini G, Mouradian MM, Juncos J, et al. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I. Ann Neurol 1988;24:366-71.
25. Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II. Ann Neurol 1988;24:372-8.
26. Bravi D, Mouradian MM, Roberts JW, Davis TL, Sohn YH, Chase TN. Wearing-off fluctuations in Parkinson disease: contribution of postsynaptic mechanisms. Ann Neurol 1994;36:27-31.
27. Rodriguez M, Lera G, Vaamonde J, Luquin MR, Obeso JA. Motor response to apomorphine and levodopa in asymmetric Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:562-6.
28. Chase TN, Mouradian MM, Engber TM. Motor response complications and the function of striatal afferent systems. Neurology 1993;43(suppl 6):S23-7.
29. Mouradian MM, Juncos JL, Fabbrini G, Chase TN. Motor fluctuations in Parkinson's disease. Ann Neurol 1989;25:633-4.
30. Nutt JG. Levodopa-induced dyskinesia: review, observations and speculations. Neurology 1990;40:340-5.
31. Quinn N, Parkes JD, Marsden CD. Control of on/off phenomenon by continuous intravenous infusion of levodopa. Neurology 1984;34:113-6.
32. Hardie RJ, Lees AJ, Stern GM. On-off fluctuations in Parkinson's disease: a clinical and neuropharmacological study, Brain 1984;107:487-506.
33. Sage JI, Trooskin S, Sonsalla PK, el al. Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism. Ann Neurol 1988;24:87-9.
34. Sage JI, McHale DM, Sonsalla P, Vitagliano D, Heikkila RE. Continuous levodopa infusions to treat complex dystonia in Parkinson's disease. Neurology 1989;39(suppl 2):60-3.
35. Frankel JP, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1990;53:96-101.
36. Stocchi F, Ruggieri S, Viselli F, et al. New trends in clinical neurology: parenteral drug therapy in spasticity and Parkinson's disease. In: Lakke JPWF, Delhaas EM, Rutgers AWF, eds. Subcutaneous lisuride infusion. The Parthenon Publishing Group, Carnforth, Lancs, U.K. 1992:205-11.
37. Baruzzi A, Contin M, Riva R, et al. Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients. Clin Neuropharmacol 1987;10:527-37.
38. Edwards LL, Quingley EMM, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology. Neurology 1992;42:726-32.
39. Valenzueda JE. Doparnine as a possible neurotransmitter in gastric relaxation. Gastroenterology 1976;71: 1019-22.
40. Kelly KA. Motiliiy of the stomach and gastroduodenal junction. In: Johnson LR, ed. Physiology of the gastrointestinal tract. New York: Raven Press, 1981:394-410.
41. Bojo L, Cassuto J. Gastric reflex relaxation by colonic distension. J Auton Nerv Syst 1992;38:57-64.
42. Nutt JG, Woodward WR, Hammerstad JP, et al. The "on-off" phenomenon in Parkinson's disease: relation to levodopa absorption and transport. N Engl J Med 1984;310:483-8.
43. 19F)-fluorodopa uptake into human brain by amino acids demonstrated by position emission tomography, Ann Neurol 1986;20:258-62.
44. Kurth MC, Tetrud LW, Irwin I, Lyness WH, Langston JW. Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations - a pilot study. Neurology 1993;43:1036-9
45. Stocchi F, Ruggieri S, Monge A, et al. Clinical efficacy of single morning doses of different levodopa formulations. Clin Neuropharmacol 1994; 17(suppl 3):S16-S20.
46. Pincus JH, Barry K. Protein redistribution diet restores motor function in patients with dopa-resistant "off" periods. Neurology 1987;38:481-3.
47. Carter JH, Nurt JH, Woodward WR, et al. Amount and distribution of dietary protein affects clinical response to levodopa in Parkinson's disease. Neurology 1989;39:552-6.
48. Jost WH, Schimrigk K. Cisapride treatment of constipation in Parkinson's disease. Mov Disord 1993;8: 339-43.
49. Djaldetti-R, Koren M, Ziv I, Achiron A, Melamed E. Effect of cisapride on response fluctuations in Parkinson's disease .Mov Disord 1995;10:81-4.
50. LeWitt PA, Ward CD, Larsen TA, et el. Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology 1983;33:1009-14
51. Langtry HD, Clissold SP. Pergolide: a review of its pharmacological properties and therapeutic potential in Parkinson's disease. Drugs 1990;39:491-506.
52. Rabey JM, Streifler M, Treves T, Korczyn AD. A long term comparative study of lisuride and levodopa in Parkinson's disease. In: Calne DB, Comi G, Crippa D, et al., eds. Parkinsonism and aging. New York: Raven Press, 1989:261-267.
53. Lera G, Vaamonde J, Muruzabal J, Obeso JA. Cabergoline: a long acting dopamine agonist in Parkinson's disease. Ann Neurol 1990;28:593-4.
54. Hutton JT, Morris JL, Brewer MA. Controlled study of the antiparkinsonian activity and tolerabiliy of cabergoline. Neurology 1993;43:613-6.
55. Rabey JM, Nissipeanu P, Inzelberg R, Korczyn AD. Beneficial effect of cabergoline, new long-lasting D-2 agonist in the treatment of Parkinson's disease. Clin Neuropharmacol 1994;17:286-93.
56. Ahlskog JE, Muenter MD, Maraganore DM, et al. Fluctuating Parkinson's disease: treatment with the long-acting dopamine agonist cabergoline. Arch Neurol 1994;51:1236-41.
57. Vidailhet MJ, Bonnet AM, Belal S, Dubois B, Marle C, Agid Y. Ropinirole without levodopa in Parkinson's disease, Lancet 1990;336:316-7.
58. 2 receptor agonist. Eur J Pharmacol 1992;215:161-70.
59. Pezzoli G, Martiginoni E, Pacchetti C, et al. Pergolide compares with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study. Mov Disord 1994;9:431-6
60. Del Pozo E, Fluckiger E, eds. Dopamine and neuroendocrine active substances. London: Academic Press, 1985.
61. Corsini GU, Del Zompo M, Gessa GL, Mangoni A. Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease. Lancet 1979;i:954-6.
62. Hornykiewicz O, Kish SJ. Biochemical pathophysiology of Parkinson's disease. Adv Neurol 1986;1987;45: 19-34.
63. Yahr M, Mendoza M, Moros D, Bergmann K. Treatment of Parkinson's disease in early and late phases: use of pharmacological agents with special reference to deprenyl (selegiline). Acta Neurol Scand 1983;(suppl 95):95-102.
64. Merello M, Lees AJ, Webster R, Bovingdon M, Gordin A. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:186-9.
65. Kaakkola S, Teravainen H, Ahtila S, Rita H, Gordin A. Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology 1994;44:77-80.
66. Ahtila S, Kaakkola S, Gordin A, et al. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after adminstration of controlled-release levodopa-carbidopa in volunteers. Clin Neuropharmacol 1995;18:46-57.
67. Limousin P, Pollak P, Pfeffen JP, Tournier-Gervason CL, Dubuis R, Perret JE. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, in Parkinson's disease. Clin Neuropharmacol 1995;18:258-65.
68. Factor SA, McAlarney T, Sanchez-Ramons JR, Weiner WJ. Sleep disorders and sleep effect in Parkinson's disease. Mov Disord 1990;4:280-5.
69. Huber SJ, Paulson GW. Management of behavioral symptoms in Parkinson's disease. In: Koller WC, ed. Therapy of Parkinson's disease. New York: Marcel Dekker, 1990:557-566.
70. Rabey JM, Treves TA, Neufeld MY, Orlow E, Korczyn AD. Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease. Neurology 1995;45:432-4.
71. Lees AJ. A sustained-release formulation of L-dopa (Madopar HBS) in the treatment of nocturnal and early-morning disabilities in Parkinson's disease Eur Neurol 1987;27:(suppl 1): 126-34.
72. Laihnen A, Alihanka J, Raitasuo, et al. Sleep movements and associated autonomic nervous activities in patients with Parkinson's disease. Acta Neurol Scand 1987;76:64-8.
73. Lhermitte F, Agid Y, Signoret JL. Onset and end-of-dose levodopa-induced dyskinesias. Arch Neurol 1978;35:261-2.
74. Bonifati V, Fabrizio E, Cipriani R, Vanacore N, Meco G. Buspirone in levodopa-induced dyskinesias. Clin Neuropharmacol 1994;17:73-82.
75. Quinn N, Marsden CD. Lithium for painful dystonia in Parkinson's disease. Lancet 1986;1:1377.
76. Bennett JP, Landow ER, Schuh LA. Suppression of dyskinesias in advanced Parkinson's disease. 2. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms. Neurology 1993;43:1551-5.
77. Bennett JP, Landow ER, Dietrich S, Schuh LA. Suppression of dyskinesias in advanced Parkinson's disease: moderate daily clozapine doses provide long-term dyskinesia reduction. Mov Disord 1994;9:409-14.
78. Price P, Parkes JD, Marsden CD. Tiapride in Parkinson's disease. Lancet 1977;2:1106.
79. Giladi N, Meer J, Honigman S. The use of botulinum toxin to treat "striatal" toes. J Neurol Neurosurg Psychiatry 1994;57:659.
80. Scholz E, Dichgans J. Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatry Neurol Sci 1985;235:60-4.
81. Friedman JH, Lannon MC. Clozapine in the treatment of psychosis in Parkinson's disease. Neurology 1989;39:1219-21.
82. Wolters EC, Hurwitz TA, Mak E, el al. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology 1990;40:832-4.
83. Kahn N, Freeman A, Juncos JL, Manning D, Watts RL. Clozapine is beneficial for psychosis in Parkinson's disease. Neurology 1991;41:1699-1700.
84. Greene P, Cote L, Fahn S. Treatment of drug-induced psychosis in Parkinson's disease with clozapine. Adv Neurol 1993;60:703-6.
85. Stocchi F, De Pandis MF, Bramante L, et al. Clozapine in Parkinson's disease. Clin Neuropharmacol (in press).
86. Livingston MG. Risperidone. Lancet 1994;1:457-60.
87. Barbato L, Monge A, Stocchi F, Nordera G. Melperone in the treatment of iatrogenic psychosis in Parkinson's disease. Funct Neurol 1996;11:201-7.
88. Zoldan J, Friedberg G, Goldbergstern H, Melamed E. Ondansetron for hallucinosis in advanced Parkinson's disease. Lancet 1993;3:562-3.
89. Quinn NP, Koller WC, Lange AE, Marsden CD. Painful Parkinson's disease Lancet 1986;1:1366-9.
90. Goetz CG, Tanner CM, Levy M, Wilson RS, Garron DC. Pain in Parkinson's disease. Mov Disord 1986;1:45-9.
91. Lang AE, Johnson K. Akathisia in idiopathic Parkinson's disease. Neurology 1987;37:477-81.
92. Ilson J, Braun N, Fahn S. Respiratory fluctuations in Parkinson's disease. Neurology 1983;33(suppl 2):113.
93. Barbeau A. The clinical physiology of side effects in long-term L-dopa therapy. Adv Neurol 1974;5:347-65.
94. Sage JI, Mark MH. Drenching sweats as an off phenomenon in Parkinson's disease: treatment and relation to plasma levodopa profile. Ann Neurol 1995;37:120-2.
95. Nissenbaum H, Quinn NP, Brown RG, Toone B, Gotham A-M. Marsden CD. Mood swings associated with the "on-off" phenomenon in Parkinson's disease. Psychol Med 1987;17:899-904.
96. Stein MB, Heuser IJ, Juncos JL, Uhde TW. Anxiety disorders in patients with Parkinson's disease. Am J Psychiatry 1990;147:217-20.
97. Steiger MJ, Quinn NP, Toone B, Marsden CD. Off-period screaming accompanying motor fluctuations in Parkinson's disease. Mov Disord 1991;6:89-90.
98. Cantello R, Gilli M, Riccio A, Bergamasco B. Mood changes associated with "end-of-dose deterioration" in Parkinson's disease: a controlled study. J Neurol Neurosurg Psychiatry1986;49:1182-90.
99. Menza MA, Sage J, Marshall E., Cody R, Duvoisin R. Mood changes and "on-off" phenomena in Parkinson's disease. Mov Disord 1990;5:148-51.
100. Brown RG, Marsden CD, Quinn N, Wyke MA. Alterations in cognitive performance and affect-arousal state during fluctuations in motor function in Parkinson's disease. J Neurol Neurosurg Psychiatry 1984; 47:454-65.
101. Gotham AM, Brown RG, Marsden CD. "Frontal" cognitive function in patients with Parkinson's disease "on" and "off" levodopa. Brain 1988;11:299-321.
102. Fitzmaurice H, Fowler CJ, Richards D, et al. Micturition disturbance in Parkinson's disease. Br J Urol 1985;57:652-6.
103. Edwards LL, Quigley EMM, Harned RK, Hofman R, Pfeiffer RF. Defecatory function in Parkinson's disease: response to apomorphine. Ann Neurol 1993;33:490-3.
104. Merello M, Leiguarda R. Adynamic bowel syndrome in Parkinson's disease with dramatic response to apomorphine Clin Neuropharmacol 1994;17:574-7.
105. Hughes AJ, Bishop S, Kleedorfer B, et al. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord 1993;8: 165-70.
106. Attanasio A, Capria C, Leggiadro G, et al. Transient cardiac arrest during continuous intravenous infusion of apomorphine. Lancet 1990;ii:1321.
107. Stibe CMH, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1988;1:403-6.
108. Poewe W, Kleedorfer B, Wagner M, Bosch S, Schelosky L. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease - long-term follow-up in 18 patients. Adv Neurol 1993;60: 656-9.
109. Gancher ST, Nutt JG, Woodward WR. Apomorphine infusional therapy in Parkinson's disease: clinical utility and lack of tolerante. Mov Disord 1995;10:37-43.
110. Ruggieri S, Stocchi F, Carta A, Catarci M, Agnoli A. Jejunal delivery of L-Dopa methyl ester. Lancet 1989;2:45-6.
111. Cooper IS. Chemopallidectomy, an investigative technique in geriatric parkinsonians. Science 1955;121: 217-8.
112. Hoehn MM, Yahr MD. Evaluation of the long term results of surgical therapy. In. Gillingham FJ, Donaldson IML, eds. Third Symposium on Parkinson's Disease. Edinburgh: E & S Livingstone, 1969: 274-80.
113. Kelly PJ, Ahlskog JE, Goerss SJ, Daube JR, Duffy JR, Kall BA. Computer-assisted stereotactic ventralis lateralis thalamotomy with microelectrode recording control in patients with Parkinson's disease. Mayo Clin Proc 1987;62:655-64.
114. Fox MW, Ahlskog JR, Kelly PJ. Stereotactic ventrolateralis thalamotomy for medically refractory tremor in post -levodopa era Parkinson's disease patients. J Neurosurg 1991;75:723- 30.
115. Diederick N, Goetz CG, Stebbins GT, el al. Blinded evaluation confirms long-term asymmetric effect of unilateral thalamotomy or subthalamotomy on tremor in Parkinson's disease. Neurology 1992;42:1311-4.
116. Narabayashi H, Yokochi F, Nakajima Y. Levodopa-induced dyskinesia and thalamotomy. J Neurol Neurosurg Psychiatry 1984;47:831-9.
117. Benabid AL, Pollak P, Gervason C, et al. Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus. Lancet 1991;337:403-6.
118. Blond S, Siegfried J. Thalamic stimulation for the treatment of tremor and other movement disorders. Acta Neurochir 1991;52:109-11.
119. Blond S, Caparros-Lefebvre D, Parker F, et al. Control of tremor and involuntary movement disorders by chronic stereotactic stimulation of the ventral intermediate thalamic nucleus. J Neurosurg 1992;77:62-8.
120. Deiber MP, Pollak P, Passingham R, et al. Thalamic stimulation and suppression of parkinsonian tremor: evidence of a cerebellar deactivation using positron emission tomography. Brain 1993;116:267-79.
121. Caparros-Lefebvre D, Blond S, Vermersch P, Pecheux N, Guieu JD, Petit H. Chronic thalamic stimulation improves tremor and levodopa induced dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 1993;56:268-73.
122. Caparros-Lefebvre D, Ruchoux MM, Blond S, et al. Long-term thalamic stimulation in Parkinson's disease: postmortem anatomoclinical study. Neurology 1994;44:1856-60.
123. Pollak P, Benabid AL, Gervason CL, Hoffmann D, Seigneuret E, Perret J. Long-term effects of chronic stimulation of the ventral intermediate nucleus in different types of tremor. Adv Neurol 1993;60:408-13.
124. Svennilson E, Torvik A, Lowe R, Leksell L. Treatment of parkinsonism by stereotactic thermolesions in the pallidal region. Acta Psychiatr Neurol Stand 1960;35:358-77.
125. Laitinen LV, Bergenheim AT, Hariz MI. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. J Neurosurg 1992;76:53-61.
126. Miller WC, DeLong MR. Parkinsonian symptomatology: an anatomical and physiological analysis. Ann N Y Acad Sci 1988;515:287-302.
127. Bergman H, Wichmann T, DeLong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 1990;249:1436-8.
128. Aziz TZ, Peggs D, Sambrook MA, Crossman AR. Lesion of the subthalamic nucleus for the alleviation of l-methyl-4-prienyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate. Mov Disord 1991;6:288-92.
129. Limousin P, Pollak P, Benazzouz A, Hoffmann D, Broussolle E, Perret JE, Benabid A-L. Bilateral subthalemic nucleus stimulation for severe Parkinson's disease. Mov Disord 1995; 10:672-4.
130. Lindvall O, Brundin P, Widner H, et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 1990;247:574-7.
131. Lindvall O, Widner H, Rehncrona S, et al. Transplantation of fetal dopamine neurons in Parkinson's disease: one-year clinical and neurophysiological observations in two patients with putaminal implants. Ann Neurol 1992;31:155-65.
132. Lindvall O, Sawle G, Widner H, et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann Neurol 1994;35:172-80.
133. Freed CR. Breeze RE, Rosenberg NL, et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. N Engl J Med 1992;327:154955.
134. Spencer DD, Robbins RJ, Naftolin F, et al. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patient with Parkinson's disease. N Engl J Med 1992;327:1541-8.
135. Widner H, Tetrud J, Rehncrona S, Snow B, Brundin P, Gustavii B. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N Engl J Med 1992;327:1556-63.
136. Kordower JH, Freeman TB, Snow BJ, et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 1995;332:118-24.
137. Fahn S. Editorial: fetal-tissue transplants in Parkinson's disease. N Engl J Med 1992;327:1589-90.
138. Goetz CG, Stebbins GT III, Klawans HL, et al. United Parkinson Foundation Neurotransplantation Registry on adrenal medullary transplants: presurgical and 1- and 2-year follow-up. Neurology 1991;41:1719-22.
139. Aebischer P, Goddard M, Signore AP, Timpson RL. Functional recovery in hemiparkinsonian primates transplanted with polymer-encapsulated PC12 cells. Exp Neurol 1994;126:151-8.
140. McRae A, Dahlstrom A. Transmitter-loaded polymeric microspheres induce regrowth of dopaminergic nerve terminals in striata of rats with 6-OH-DA induced parkinsonism. Neurochem Int 1994;25:27-33.
141. Kang UJ, Fisher LJ, Joh TH, O'Malley KL, Gage FH. Regulalion of dopamine production by genetically modified primary fibroblasts. J Neursci 1993;13:5203-11.
142. Anton R, Kordower JH, Maidment NT, et al. Neural-targeted gene therapy for rodent and primate hemiparkinsonism. Exp Neurol 1994;127:207-18.
143. During MJ, Naegele JR, O'Malley KL, Geller AI. Long-term behavioral recovery in parkinsonian rates by an HSV vector expressing tyrosine hydroxylase. Science 1994;266:1399-1403.
144. Hoffer BJ, Hoffman A, Bowenkamp K, et al. Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci Lett 1994;182:107-11.
145. Hefti F. Neurotrophic factor therapy for nervous system degenerative diseases. J Neurobiol 1944;25:1418-35.
146. Barinaga M. Researches broaden the attack on Parkinson's disease. Science 1995;267:455-6.